Alentis and PinotBio Announce Collaboration to Develop Next-Generation ADCs Targeting claudin-1 October 14, 2026 Alentis Therapeutics and PinotBio today announced they have entered into a research collaboration and licensing agreement to discover and develop next-generation antibody-drug conjugates (ADCs) to expand the potential of claudin-1 as a therapeutic target in oncology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013853948/en/ Claudin-1 is overexpressed in more than ten different [...]
e.l.f. Brands Hits the Pitch for Year Two with Tottenham Hotspur Women October 13, 2026 e.l.f. returns as Official Back of Shirt Sponsor for the 2026-2027 season, building on its commitment to empower.legendary.females.
Artificial is a terrifying look at AI – and the year’s most important film October 13, 2026 Artificial film review and star rating as OpenAI movie premieres at the London Film Festival: ★★★★★ It isn’t typically a film’s duty to push a political agenda, but with Artificial, the biopic of OpenAI co-founder Sam Altman, there is a clear call to action. It is inevitable that people will ask: ‘What can this film [...]
Lubrizol Launches the ZYRA™ Family of Products for Crop Care Agriculture Formulation Technologies October 13, 2026 Lubrizol’s agriculture solutions bring decades of formulation science and specialty chemistry expertise to the evolving needs of crop care formulators. The ZYRA™ family of products helps agricultural manufacturers improve formulation performance, stability and efficiency across a wide range of applications. From crop protection and plant nutrition to seed treatment and biologicals, Lubrizol partners with customers to simplify formulation complexity and accelerate innovation.
Manchester – not London – is Europe’s top nightlife city October 13, 2026 Manchester enjoys more after-hours fun than any European city, according to an analysis of lift and escalator journeys around Europe. According to the elevator manufacturer Kone, Britain’s third-largest urban hub is referred to as the continent’s “after-hours City”, with more than four per cent of lift journeys taken between midnight and 4am – which is [...]
Saudi Fund for Development Announces Progress on Pristina–Mitrovica Highway Project in Kosovo October 13, 2026 The Saudi Fund for Development (SFD) today joined the Government of Kosovo to inaugurate the Pristina–Mitrovica Highway, marking SFD’s first completed project in Kosovo and an important milestone in the partnership between both sides. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013433726/en/ His Excellency Sultan bin Abdulrahman Al-Marshad, Chief Executive Officer of [...]
KAST Selects Kiln’s Claire Wells as Chief Legal Officer October 13, 2026 KAST adds an experienced CLO to help drive the next phase of growth The hire further enhances KAST’s robust compliance function Wells is leading the charge to add additional licenses throughout the world
Foundever Appoints Pierre Barrial as Chief Executive Officer to Lead Next Phase of Sustainable Growth and CX Transformation for the World’s Leading Brands October 13, 2026 Experienced global executive joins to deepen client partnerships, drive operational excellence and advance CX at scale
Options Announces the Opening of a New London Office in the Heart of Covent Garden October 13, 2026 Options Technology, the leading provider of trading infrastructure to the global financial markets, today announced the opening of their new London office at 11 Strand. The new office, located in the heart of Covent Garden, is designed to complement their existing office at 100 Bishopsgate by offering proximity to both Buy and Sell side clients, [...]
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research October 13, 2026 — Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be Shared in Oral Presentation — — Detailed Positive Results From REVITALYZSM Phase 3 Study Evaluating LUMRYZ in Adults With Idiopathic Hypersomnia to be Shared in Oral Presentation —